Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • PRO.MED.CS Praha

    PRO.MED.CS Praha a.s. is a Czech pharmaceutical Company located in Prague specialising in the manufacture of solid medicinal forms – tablets, film coated tablets and capsules. Our medicinal portfolio is primarily aimed at the cardiovascular, gastrointestinal and musculoskeletal areas and pain. We also provide medicines for mental disorders, bacterial and viral diseases. In addition to prescription medicines we produce over the counter medicines and trace elements too.

    This is a FREE LISTING on PMHUB

    Below are full profiles from other companies in related areas

    No items found

    Company Details

    PRO.MED.CS Praha
    Telcska 1, Prague, 140 00, Czech Republic
    +420 241 013 111
    Contact PRO.MED.CS Praha
    Website

     Latest Content from PMHub 

    Inizio Ignite Sparks a New Era of Connected Advisory Solutions

    Press Releases | January 7, 2026 | Inizio

    Inizio, a leading global commercialization partner for pharma and life sciences, today unveiled Inizio Ignite, a reimagined, fully integrated advisory partner designed to accelerate pharma performance through strategy, insights, and innovation.

    MM+M Podcast explores AI-powered audience intelligence with Inizio Evoke

    Press Releases | January 7, 2026 | Inizio

    The MM+M Podcast features a conversation with Jamie Avallone, Chief Data Officer at Inizio Evoke, and Iris Lin, Product Science Lead at Inizio Evoke, who share their perspectives on what...

    Uncovering Inequities in Alzheimer’s Disease Screening and Care

    Press Releases | January 6, 2026 | Medscape Education

      On December 5, MAPS hosted an educational webinar exploring recent research in Alzheimer’s disease (AD) screening, testing, and treatment. Experts from Komodo Health and Medscape shared findings from their...

    Five Predictions That Will Reshape Biopharma Commercialisation in 2026

    White Papers and Resources | January 5, 2026 | Nmblr

    Every year, we’re met with restructuring, hiring freezes, and portfolio cuts. And every year we tell ourselves the same story. It’s a rough patch. A cycle that will reverse. But...

    Where Are We Today With Artificial Intelligence (AI) in Rare Disease Diagnosis and Care?

    Press Releases | December 23, 2025 | Medscape Education

    Discover how AI-powered tools are transforming rare disease diagnosis, patient care, and clinical decision-making.

    Does Rare Disease Education Work?

    Press Releases | December 23, 2025 | Medscape Education

    For a child with a rare disease, a doctor’s continuing education can end a years-long diagnostic odyssey and unlock access to vital care.

    From Genetic Puzzles to Precision Therapeutics

    Press Releases | December 23, 2025 | Medscape Education

    How was a new rare disease discovered through Singapore’s Undiagnosed Disease Program? And how will technology allow us to change how we discover rare diseases in the future? Read more...

    Medscape and the GNNRD: Empowering Nurses With a Rare Disease Education Series

    Press Releases | December 23, 2025 | Medscape Education

    Nurses play a vital and multifaceted role in rare disease care, providing consistent patient support, education, and care coordination, and ongoing education is essential to empower them to meet the...

    What Is the RDI-Lancet Commission for Rare Disease and What Will It Achieve?

    Press Releases | December 23, 2025 | Medscape Education

    Christy Rohani-Montez, Medscape’s Rare Disease Education Lead recently spoke with Dr Lucy McKay, CEO, and Megan Pullein, Strategic Operations Officer from the UK-based charity Medics for Rare Disease (MfRD). We...

    Pharma’s digital dilemma: Finding the balance between speed, scale, and experience

    Videos and Podcasts | December 19, 2025 | Graphite Digital

    What’s holding pharma back from true digital transformation? At NEXT Pharma 2025, Our CEO Rob Verheul and Roeland van der Heiden (AstraZeneca) argued it starts with design systems. This quick...